36
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1474 |
LXW7
|
Integrin | Cytoskeletal Signaling |
LXW7 是一种整合素αvβ3抑制剂,是含 Arg-Gly-Asp (RGD) 的环状肽,对αvβ3整联蛋白具有很高的结合亲和力,IC50为 0.68 μM。它可增强 VEGFR-2 磷酸化和 ERK1/2 活化,具有抗炎活性。 | |||
T6812L |
Cyclo(-RGDfK) TFA
|
Integrin | Cytoskeletal Signaling |
Cyclo(-RGDfK) TFA 是一种选择性整合素αvβ3的有效抑制剂,其IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。 | |||
T6812 |
Cyclo(-RGDfK)
Cyclo (-RGDfK) |
Integrin | Cytoskeletal Signaling |
Cyclo(-RGDfK) (Cyclo (-RGDfK)) 是一种选择性整合素αvβ3的有效抑制剂,IC50值为 0.94 nM。它通过与细胞表面的 αvβ3 整合素结合,特异性靶向肿瘤微血管和癌细胞。 | |||
T83034 |
Anti-Mouse TCR V gamma 2 Antibody (UC3-10A6)
|
||
Anti-Mouse TCR V gamma 2 Antibody是一种针对小鼠TCR V gamma 2的IgG类型的抗体抑制剂,其宿主为Armenian Hamster。 | |||
TP1879L1 |
P11 acetate
|
Integrin | Cytoskeletal Signaling |
P11 acetate 是一种整合素 αvβ3-玻连蛋白相互作用拮抗剂 (IC50 = 2.74 nM)。 | |||
T6813 |
Cyclo(RGDyK) trifluoroacetate
Cyclo(RGDyK) |
Integrin | Cytoskeletal Signaling |
Cyclo(RGDyK) trifluoroacetate 是一种选择性αVβ3整联蛋白抑制剂,IC50为 20 nM。 | |||
T2494 |
Cilengitide
西仑吉肽,EMD 121974 |
Integrin; Autophagy | Autophagy; Cytoskeletal Signaling |
Cilengitide (EMD 121974) 是一种有效的 αvβ3/5 受体整合素抑制剂,可抑制 ανβ3和 ανβ5与玻连蛋白结合,IC50值分别为 4 和 79 nM。 | |||
T6657 |
SB273005
|
Integrin | Cytoskeletal Signaling |
SB273005 是一种有效的整合素抑制剂,对 αvβ3 受体和 αvβ5 受体的 Ki 分别为 1.2 nM 和 0.3 nM。 | |||
TQ0250 |
CWHM-12
|
Integrin | Cytoskeletal Signaling |
CWHM-12 是 αV 整合素的有效抑制剂,抑制αvβ8、αvβ3、αvβ6和αvβ1,IC50 为 0.2、0.8、1.5 和 1.8 nM。 | |||
T16085 |
MK-0429
L-000845704 |
Others | Others |
MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM). | |||
TP2148 |
LXW7 TFA (1313004-77-1 free base)
LXW7 TFA |
Integrin | Cytoskeletal Signaling |
LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2. | |||
T6806 |
Cilengitide TFA
|
Integrin; Autophagy | Autophagy; Cytoskeletal Signaling |
Cilengitide TFA 是一种选择性的 αvβ3和 αvβ5受体整合素抑制剂,IC50分别为 4 nM 和 79 nM。对 GP IIb/IIIa 的选择性约为 10 倍。 | |||
TP1459L |
Gly-Arg-Gly-Asp-Ser acetate(96426-21-0 free base)
|
Integrin | Cytoskeletal Signaling |
Gly-Arg-Gly-Asp-Ser acetate(96426-21-0 free base) 是一种源自纤连蛋白的细胞结合区域的细胞结合蛋白结构域。 | |||
TP1879 |
HSDVHK-NH2
P11 |
||
Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic. | |||
T16851 | SB-267268 | Others | Others |
SB-267268 inhibits human and mouse αvβ3 (IC50s: 0.68 and 0.29 nM, respectively). SB-267268 is a selective and nonpeptidic alpha(v)beta3 and alpha(v)beta5 integrins antagonist (Kis: 0.9, 0.5 and 0.7 nM for human αvβ3, monkey αvβ3 and human αvβ5, respective | |||
TP2390 |
Maraciclatide
NC-100692,NC 100692,NC100692 |
||
Maraciclatide is a radiopharmaceutical targeting αvβ3 integrin. | |||
T11663 | Integrin-IN-2 | Others | Others |
Integrin-IN-2 is an orally bioavailable pan αv integrin inhibitor.Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively. | |||
T8726 |
Cyclo(RGDyK)
|
Integrin | Cytoskeletal Signaling |
Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM. | |||
T15584 |
Integrin Antagonists 27
|
Others | Others |
Integrin Antagonists 27 is a small molecule integrin αvβ3 antagonist. It has a binding affinity of 18 nM and as a novel anticancer agent. | |||
T69460 |
TSRI265
|
||
TSRI265 is a novel αvβ3 ligand, disrupting the integrin-MMP2 interaction and showing antiangiogenic activit, inhibiting angiogenesis and tumor growth in vivo. | |||
T82516 |
E(c(RGDfK))₂
|
||
E(c(RGDfK))是一种针对αvβ3整联蛋白的特异性结合片段,表现出对肿瘤的靶向作用。在人卵巢癌OVCAR-3异种移植肿瘤模型中,该化合物的摄取有所提升,适用于癌症研究领域。 | |||
T68462 |
D-Ornithine lactam
|
||
D-Ornithine lactam is a building block. It has been used in the synthesis of hepatitis C virus non-structural protein 5B inhibitors, as well as αVβ3 integrin receptor antagonists. | |||
T75990 |
Cyclo(Arg-Gly-Asp-D-Phe-Val)
|
||
Cyclo(Arg-Gly-Asp-D-Phe-Val) 为一种整合素αvβ3抑制剂,具有抗肿瘤活性,并可用于急性髓系白血病的研究。 | |||
T76068 |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
|
||
Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA 是一种环状RGD多肽, 对αvβ3有高亲和性,能干扰细胞整合素之间的相互作用。此化合物能抑制胚胎干细胞(ESC)的多潜能性基因表达,并可在体内减少mESC的致瘤潜力,因此适用于肿瘤研究领域。 | |||
T76807 | Etaracizumab | ||
Etaracizumab (LM 609),一种αvβ3整合素IgG1单克隆抗体,具有抑制血管生成和黑色素瘤生长的作用,可用于抗癌研究。 | |||
T75835 |
HSDVHK-NH2 TFA
|
||
HSDVHK-NH2 TFA 作为一种整合素 αvβ3-玻璃体结合蛋白的互作拮抗剂,其IC50值达到1.74 pg/mL (2.414 pM)。 | |||
T10920 |
Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
|
Others | Others |
Arg-Gly-Asp-D-Phe-Val (TFA) has anti-tumor activity and is an inhibitor of integrin αvβ3. | |||
T75724 |
LXW7 TFA
|
||
LXW7 TFA, 包含 Arg-Gly-Asp (RGD) 的环状肽,作为整合素αvβ3抑制剂,展示出对αvβ3整联蛋白高度的结合亲和力,其IC50值为0.68 μM。此外,LXW7 TFA 能够促进 VEGFR-2 磷酸化和 ERK1/2 激活,显示出抗炎活性。 | |||
T74400 | TC113 | ||
TC113是一种与c(RGDyK)偶联的Gemcitabine。它通过整合素αvβ3可被A549细胞内化。此外,TC113对WM266.4和A549细胞表现出显著的抗增殖效果。 | |||
TP1974 |
Obtustatin
|
||
Highly potent integrin α1β1 inhibitor (IC50 = 0.8 nM for α1β1 binding to type IV collagen). Selective for α1β1 over α2β1, αIIbβ3, αvβ3, α4β1, α5β6, α9β1 and α4β7. Inhibits FGF2-stimulated angiogenesis in the chicken chorioallantoic model. Displays antitum | |||
T78064 |
Synstatin (92-119)
SSTN92-119 |
Integrin | Cytoskeletal Signaling |
Synstatin (92-119)为一种抗肿瘤化合物,它能够抑制血管生成与癌细胞侵袭,通过下调整合素αvβ3,降低VEGF与FGF-2的活化。 | |||
T83736 |
RTDLDSLRTYTL TFA
|
||
RTDLDSLRTYTL是一种αVβ6整合素配体。它选择性地抑制纤维连接蛋白与αVβ6整合素的结合,相比之下,对于纤维连接蛋白与αVβ3或αVβ5以及纤维蛋白原与αIIβ3的结合则几乎不产生影响(IC50分别为0.02, >50, >50, 和 >50 µM)。此外,RTDLDSLRTYTL还能以浓度依赖的方式抑制HT-29结肠癌细胞与纤维连接蛋白的结合。 | |||
T75761 |
Gly-Arg-Gly-Asp-Ser TFA
GRGDS TFA |
||
Gly-Arg-Gly-Asp-Ser (TFA) 是一种与糖蛋白和骨桥蛋白在细胞结合域中起作用的五肽。该化合物能够与整合素整联蛋白受体αvβ3和αvβ5结合,其IC50值分别约为5 μM和6.5 μM。 | |||
TP2098 |
Echistatin
Echistatin, α1 isoform |
||
Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) | |||
T70368 |
SF0166
|
||
SF0166 是一种有效的选择性 αvβ3拮抗剂,对于 αvβ3,αvβ6,和 αvβ8的IC50值分别为 0.6 nM, 8 nM 和 13 nM。SF0166 抑制人、大鼠、兔和狗细胞系中玻连蛋白的细胞粘附,IC50值为 7.6 pM 至 76 nM。SF0166 在氧诱导视网膜病变小鼠模型中减少新生血管。 | |||
TP1343 |
RGD Trifluoroacetate
|
||
RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; RGD Trifluoroacetate binds to integrins.RGD Trifluoroacetate is the most effective and most often employed pept |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36715 |
Tetrac
Tetraiodothyroacetic acid,3,3',5,5'-Tetraiodothyroacetic acid |
Apoptosis; EGFR | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tetrac (Tetraiodothyroacetic acid)是L-甲状腺素(T4)的衍生物,是一种甲状腺整合素受体拮抗剂。Tetrac通过阻断EGFR介导的结直肠癌细胞信号传导来诱导抗增殖。Tetrac 可阻断 T4 和 3,5,3'-triiodo-L-thyronine (T3)在细胞表面甲状腺素整合素 αvβ3 受体上的作用。Tetra 具有抗血管生成、抗肿瘤活性和促凋亡活性。 | |||
TN5221 | (-)-Variabilin | ||
Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3.Variabilin is also an antimicrobial furanosesterterpene. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro a... | |||
T36295 | Echistatin TFA | ||
Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1[1][2][3][4]. [1]. J Musial, et al. Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins. RGD-containing peptides from viper venoms. Circulation. 1990 Jul;82(1):261-73.[2]. ... |